Effect of Treatment on Steroidome in Women with Multiple Sclerosis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F25%3A43928260" target="_blank" >RIV/00064173:_____/25:43928260 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/25:10496059 RIV/00216208:11120/25:43928260 RIV/00216208:11130/25:10496059 RIV/00023761:_____/25:N0000004 and 2 more

Result on the web

<a href="https://doi.org/10.3390/ijms26051835" target="_blank" >https://doi.org/10.3390/ijms26051835</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/ijms26051835" target="_blank" >10.3390/ijms26051835</a>

Result language

angličtina

Original language name

Effect of Treatment on Steroidome in Women with Multiple Sclerosis

Original language description

Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease of the central nervous system. The manifestation of MS is related to steroid changes during the menstrual cycle and pregnancy. As data focusing on the effect of anti-MS drug treatment on steroidome are scarce, we evaluated steroidomic changes (79 steroids) in 61 female MS patients of reproductive age 39 (29, 47) years (median with quartiles) after treatment with anti-MS drugs on the GC-MS/MS platform and immunoassays (cortisol and estradiol). The changes were assessed using steroid levels and steroid molar ratios (SMRs) that may reflect the activities of steroidogenic enzymes (SMRs). A repeated measures ANOVA, followed by multiple comparisons and OPLS models, were used for statistical analyses. The anti-MS treatment decreased steroid levels in the follicular phase. Anti-CD20 monoclonal antibodies (mAb), such as ofatumumab and ocrelizumab; inhibitors of the sphingosine-1-phosphate receptor (S1PRI); and IFNβ-1a decreased circulating 17-hydroxy-pregnanes and shifted the CYP17A1 functioning from the hydroxylase- toward the lyase step. Decreased conjugated/unconjugated steroid ratios were found after treatment with anti-MS drugs, especially for glatiramer acetate and anti-CD20 mAb. In the luteal phase, IFN-β1a treatment increased steroidogenesis; both IFN-β1a and ocrelizumab increased AKR1D1, and S1PRI increased SRD5A functioning. Anti-CD20 mAb reduced the functioning of enzymes catalyzing the synthesis of immunomodulatory 7α/β and 16α-hydroxy-androgens, which may affect the severity of MS. The above findings may be important concerning the alterations in bioactive steroids, such as cortisol; active androgens and estrogens; and neuroactive, neuroprotective, and immunomodulatory steroids in terms of optimization of anti-MS treatment.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30210 - Clinical neurology

Project

<a href="/en/project/NU20-04-00450" target="_blank" >NU20-04-00450: Hormonal alterations in patients with multiple sclerosis</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

International Journal of Molecular Sciences

ISSN

1661-6596

e-ISSN

1422-0067

Volume of the periodical

26

Issue of the periodical within the volume

5

Country of publishing house

CH - SWITZERLAND

Number of pages

34

Pages from-to

1835

UT code for WoS article

001442584100001

EID of the result in the Scopus database

2-s2.0-86000788372